Brickell Biotech Inc

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in September 2009 and is headquartered in Boulder, CO.

Aikido Pharma Inc.

Kelso Technologies

Oragenics

Penny stocks on Robinhood are a big focus for Reddit traders in April The post 4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now

BIOLASE

Biotech stocks are more popular than ever; here are 3 to watch under $5 The post Biotech Penny Stocks To Buy? 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks To Buy? 3 to Watch Under $5

Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment

Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis

BOULDER, Colo., April 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that results from the US Phase 3 open-label long-term (12-month) safety study of sofpironium bromide gel, 5% and 15% were selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology's (AAD) 2021 Virtual Meeting Experience (VMX) being held April 23– 25, 2021. Also, as one of the top twelve late-breaking research abstracts, Brickell has been invited to participate in a live Q&A session on April 24th from 2:00 PM – 3:00 PM CT.

Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology's 2021 VMX

The stock price of Brickell Biotech Inc (NASDAQ: BBI) has increased by over 8% pre-market. This is why it happened.

BBI Stock Price Increases Over 8% Pre-Market: Why It Happened

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q4 2020 Results - Earnings Call Transcript

Initiated U.S. pivotal Phase 3 clinical program (Cardigan I and II studies) evaluating sofpironium bromide gel, 15% for the treatment of primary axillary (underarm) hyperhidrosis

Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Webinar taking place on Friday, March 26th @ 10 am EDT Webinar taking place on Friday, March 26th @ 10 am EDT

Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market

BOULDER, Colo., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2020, after the market close on Tuesday, March 9, 2021. Brickell's management will host a conference call and webcast at 4:30 pm ET on Tuesday, March 9th to discuss the financial results and recent corporate highlights.

Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021

T opline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5% (ECCLOCK ® ) recently launched in Japan by development partner, Kaken Pharmaceutical

Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study

Kaken plans to launch ECCLOCK ® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020 - - - ECCLOCK ® placed on Japan's National Health Insurance (NHI) drug reimbursement price list

Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical

BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in the Piper Sandler 32nd Annual Healthcare Conference taking place December 1-3, 2020.

Brickell Biotech to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q3 2020 Results - Earnings Call Transcript

Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021 - - - Initiated the Cardigan I study, the first of two U.S. pivotal Phase 3 clinical studies evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis - - - On track to initiate the Cardigan II study, the second U.S. pivotal Phase 3 clinical study, later this year - - - Planned commercial launch of ECCLOCK® in Japan by development partner, Kaken, expected by the end of 2020, which follows regulatory approval received in the third quarter

Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update

BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the third quarter ended September 30, 2020, after the market close on Thursday, November 12, 2020. Brickell's management will host a conference call and webcast at 4:30 pm ET on Thursday, November 12th to discuss the financial results and recent corporate highlights.

Brickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020

BOULDER, Colo., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced the pricing of an underwritten public offering of 20,833,322 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 20,833,322 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one, immediately exercisable investor warrant with a five year term to purchase one share of common stock at an exercise price of $0.72 per share. The shares and warrants are being sold at a combined offering price of $0.72, for total gross proceeds of approximately $15.0 million, before underwriting discounts and commissions and offering expenses payable by Brickell. The offering is expected to close on or about October 27, 2020, subject to the satisfaction or waiver of customary closing conditions.

Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering

Primary axillary h yperhidrosis is estimated to affect over 1 0 million p eople in the U.S .

Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Japan is the first country to approve sofpironium bromide  with  commercial launch  expected  later this year

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical

BOULDER, Colo., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in the 4th Annual Lake Street Best Ideas Growth Conference and the Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit, both being held in September 2020.

Brickell Biotech to Participate in September Virtual Investor Conferences

Advancement of the U.S. based program will be dependent upon results generated from AnGes’ ongoing and planned clinical studies in Japan Advancement of the U.S. based program will be dependent upon results generated from AnGes’ ongoing and planned clinical studies in Japan

AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S.

Claims directed to novel crystalline forms of sofpironium bromide

Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2020 Results - Earnings Call Transcript

Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020  by development partner, Kaken   Kaken to receive regulatory decision in Japan for sofpironium bromide gel as early as the fourth quarter of 2020   Brickell plans to initiate its U.S. pivotal Phase 3 program in the fourth quarter of 2020

Brickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update

BOULDER, Colo., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Wednesday, August 12, 2020. Brickell’s management will host a conference call and webcast at 4:30pm ET to discuss the financial results and recent corporate highlights.

Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020

BOULDER, Colo., June  17, 2020  (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced the pricing of an underwritten public offering of 17,500,000 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 17,500,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase one share of common stock at a combined offering price of $1.15, for total gross proceeds of approximately $20.1 million, before underwriting discounts and commissions and offering expenses payable by Brickell.  The offering is expected to close on or about June 22, 2020, subject to the satisfaction or waiver of customary closing conditions.     

News for Brickell Biotech Inc Stock (BBI)